Tech Company Financing Transactions
Precisio Biotix Therapeutics Funding Round
Bill & Melinda Gates Foundation participated in a funding round for Precisio Biotix Therapeutics. The round closed on 6/16/2025.
Transaction Overview
Company Name
Announced On
6/16/2025
Transaction Type
Debt
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The funding will specifically support the discovery of optimized and validated lead (engineered) lysins against critical BV pathogens by the end of 2025, setting the stage for clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Dover, DE Undisclosed
USA
Dover, DE Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Precisio Biotix Therapeutics ("Precisio") is a US-incorporated industry leader in precision antibacterial biological solutions; specifically, the identification and development of lysin, amurin, and phage solutions and related delivery technologies to combat bacterial infections and address related unmet medical needs. Precisio is a platform-plus-product drug discovery and development company, with both Rx and consumer products. Precisio can provide low-cost antibacterials for most of the world.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Engel
Browse more venture capital transactions:
Prev: 6/16/2025: Pano AI venture capital transaction
Next: 6/16/2025: Lumion venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs